Skip to main content
. 2015 Jan 30;6(4):646–657. doi: 10.1021/cn500367b

Figure 4.

Figure 4

Concentration–response curves of agonist-stimulated [35S]GTPγS binding in the presence of indicated concentrations of AT-076 at the mu (A), delta (B), kappa (C), and nociceptin (D) opioid receptors and JDTic at the NOP receptor (E). The respective agonists used were as follows: nociceptin, GGFTGARKSARKLANQ for NOP; U69,593, (5a,7a,8b)-(−)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4,5]dec-8-yl]benzeneacetamide for KOP; DAMGO, [d-Ala2, NMe-Phe4, Gly-ol5]-enkephalin for MOP; DPDPE, [d-Pen2,d-Pen5]enkephalin for DOP. For calculation of the Ke values, the experimentally determined EC50 values of the subtype-specific agonists are as follows: nociceptin, 2.76 nM; U69,593, 26.87 nM; DAMGO, 19.78 nM; DPDPE, 4.65 nM.